(Q38295822)

1 September 2017

1 reference

title

Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals (English)

1 reference

1 September 2017

1

Jürgen K Rockstroh

1 reference

1 September 2017

publication date

1 January 2015

1 reference

1 September 2017

1 reference

1 September 2017

volume

35 Suppl 1

1 reference

1 September 2017

page(s)

51-55

1 reference

Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?

1 September 2017

cites work

1 reference

Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000.

21 January 2018

1 reference

HIV and viral hepatitis coinfections: advances and challenges

21 January 2018

1 reference

Managing HIV/hepatitis C co-infection in the era of direct acting antivirals

21 January 2018

1 reference

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis

21 January 2018

1 reference

Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection

21 January 2018

1 reference

HCV direct-acting antiviral agents: the best interferon-free combinations

21 January 2018

1 reference

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12721

1 reference

1 September 2017

1 reference